Phase I is a dose escalation study to assess the safety and tolerability, and to determine the MTD or MAD and RP2D of BB-1705.~Phase II is a cohort expansion study to explore one or more RP2Ds to further assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Patients with locally advanced and unresectable or metastatic solid tumors who have progressed on prior lines of standard of care therapies will be enrolled in this study if eligible.
The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).